Annovis Bio, Inc. - 8-K Filing
Annovis Bio reports preliminary cash and cash equivalents of approximately $2.8 million as of September 30, 2026. (Items: 7.01 Regulation FD Disclosure, 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7, 8.01 Other Events)
Tickers: $ANVS